Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Adicionar filtros








Intervalo de ano
1.
China Pharmacy ; (12): 527-531, 2020.
Artigo em Chinês | WPRIM | ID: wpr-817303

RESUMO

OBJECTIVE:To p rovide reference for related pharmacy work for developing evidence-based pharmacy information support to respond for novel coronavirus pneumonia (COVID-19) epidemic. METHODS :The PubMed,CNKI and Wanfang database were consulted to obtain treatment progress of COVID-19,prohibited for use with lopinavir/ritonavir and adverse drug reactionas until February 12,2020;so were package insert and UpToDate at the same time. Those information were summarized and evaluated. RESULTS & CONCLUSIONS :Totally 14 literatures introduced chemical drugs for COVID- 19,involving 7 categories, 20 kinds of chemical drugs as antiviral drugs (interferon α/interferon α-2 β , lopinavir/litonavir, etc.), immunomodulatory agents (such as glucocorticoid ,gamma globulin ),antimalarial drugs (such as chloroquine phosphate ). The existing evidence of drug treatment mainly comes from in vitro cell test or currently progressing RCT ,with low-level evidence and recommendation intensity (Oxford evidence level is level 5,recommendation intensity is level D ). For lopinavir/ritonavir that recommended in the diagnosis and treatment recommendations for COVID- 19 published by the National Health Commission ,it is a CYP3A inhibitor ,which resulted in increased plasma concentrations of some medications such as antiarrhythmic drugs ,antitumor targeted drugs and antibacterial drugs ,and should not be used in combination with drugs such as afzosin ,ivabradine,amiodarone, etc. Its common adverse reactions mainly involved igestive system (diarrhea,taste disorders ,vomiting,etc.),respiratory system (upper respiratory tract infection ),endocrine and metabolic system (hypercholesterolemia,etc.),skin and its appendents (skin rash),which should be monitored clinically.

2.
Artigo em Inglês | IMSEAR | ID: sea-153834

RESUMO

Background: Package inserts are the authentic source of information for the new molecules in the market. Incomplete and incorrect product information may promote irrational prescribing and may have serious consequences. Hence, our aim was to analyse and compare the information supplied in the package insert according to the section 6.2 and section 6.3 of schedule D of Drugs and Cosmetic Act, 1940 in public (government) and private (non-government) sector. Methods: Package inserts of allopathic drugs which were supplied by government from drug store of tertiary care centre and hospital and from pharmacies on request were collected. A total of 270 package inserts in English were collected that is 38 from government hospital and 232 from the pharmacies nearby the hospital. The package inserts were analysed for the presentation of completeness of the information as per section 6.2 and 6.3. Results: The presentation of information on analysing 233 package inserts (28 government and 205 non government) was not uniform and it was difficult to locate and retrieve information easily due to lack of common layout and heading. Moreover, the package inserts were of variable shape and size with different font size which made it inconvenient for analysing as well as for reference. Posology and method of administration was incomplete in 3% package insert in non- government cases whereas in government supply it was 7%. Use of drug in pregnancy and lactation was deficient in 11% and 14% packages inserts of non-government sources and government sources respectively. Instructions for use were lacking in 25% and 29% package inserts of government and non-government sources respectively. Conclusions: The need of the hour is to further refine contents of the circulated package inserts to make them complete, reliable and up to date. This can be a step forward for ethical and effective dissemination of healthcare services in our growing society.

3.
China Pharmacy ; (12)1991.
Artigo em Chinês | WPRIM | ID: wpr-526844

RESUMO

OBJECTIVE:To facilitate the evolvement of hospital pharmaceutical care.METHODS:The website of pharmacy department of Shanghai No.9People’s Hospital was programmed and exploited,and based on which the hospital pharmaceutical information service was carrying out.RESULTS:The website ran stably and fast;its maintenance was very convenient;pharmaceutical information was rich,the online communication between doctors and patents was available here and the application outcome proved to be satisfactory.CONCLUSION:Establishing hospital pharmaceutical website and carrying out online pharmaceutical care are of significance in the evolvement of hospital pharmacy work.

4.
China Pharmacy ; (12)1991.
Artigo em Chinês | WPRIM | ID: wpr-522843

RESUMO

OBJECTIVE:To promote the development of hospital pharmaceutical information service(HPIS)and to bring pharmacists into full play in pharmaceutical service.METHODS:This article analyzed the running program of hospital pharmaceutical information and the existing problems in HPIS.RESULTS:New pattern of HPIS was put forward.CONCLUSION:HPIS is very important and should be promoted greatly.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA